Medicine, the editor stated, "Insurance companies should not be allowed to reap the benefits of the academic centers without paying the price".3 Whether the price will mean a higher reimbursement for each individual component of care or a premium tax on the insurance companies is immaterial to me. We must recognize that treating academic centers the same as private sector managed-care will impede the advances in medicine for which the United States is known. There is evidence that up-to-date cutting edge care is superior.4-6 Should not the reimbursement be superior also and sufficient to allow the academic specialist to augment but not compete with the primary care physician?
My view of academic medicine is old-fashioned, I admit. The most difficult, complicated, perhaps hopeless cases should be sent to the academic medical center. Teaching services should exist where educated academic physicians can teach medical students and house staff the principles of modern medicine and in so doing treat and cure these complicated patients.7 Follow-up care is best provided by the private sector. Lastly, the support for such academic ventures should be provided by relief from bureaucratic constrictions that make no sense, proper reimbursement for care that is out of the ordinary, and the financial recognition that teaching and research are worthwhile endeavors and are the vehicles that have driven American medicine to the forefront.
Although this argument may seem idealistic or oldfashioned to many people in the 1990s, that doesn't make it wrong. To effect such a system would require the cooperation and understanding of multiple institutions. Certainly the sponsors of the academic health center (private, state) must recognize the importance of the venture and financially support it. Second, the insurance companies must ante up in some way. Third, the federal government should not forget that training physicians costs money and should continue the subsidy for training that has previously existed. I would, however, direct the payments to the medical school rather than the hospital administration as has been done in the past. Finally, the country should CHEST / 107 / 3/ MARCH, 1995 593 acknowledge that the academic health system has produced the finest medicine in the world. It is not the cheapest, but it is the best. Without an understanding of what has produced this lofty position, we will degenerate into a pure competition with private practice and the new advances will cease-a process that I believe is already happening.
A (02), is inhaled as the predominant component of photochemical air pollution. Ozone is categorized as a secondary air pollutant, being derived from photochemical reactions of nitrogen oxides and volatile organic compounds in the troposphere. Although significant progress in reducing 03 levels has occurred, even in Los Angeles, millions of Americans continue to be exposed to ambient concentrations above the health-based federal standard, which is 0.12 part per million (ppm) for 1 h, not to be exceeded more than once a year. These "exceedances" may occur at least a few days per year in numerous urban and rural areas throughout the country, and more than 100 days annually near Los Angeles. It is not surprising that 03 has generated a great deal of public health concern, continuing regulatory efforts, and research involving animal toxicology, controlled (clinical) exposures, and epidemiology.1-3
Human volunteers exposured to controlled 03 levels .0.40 ppm experience short-term decrements of lung function that vary widely between different subjects but are reproducible over time in a given individual.4 McDonnell et a15 retrospectively investigated numerous characteristics that might predict individual differences in acute response (FEV1) among 290 03-exposed healthy male volunteers aged 18 to 32. Besides 03 concentration, only age was a significant predictor, ie, response decreased with increasing age. The carefully performed, prospective study by Aris and coworkers (see page 621) confirms and extends previous work regarding the poor predictability of individual responses to 03. Methacholine responsiveness did not predict 03-induced lung function responses, nor did respiratory symptoms correlate well with the lung function changes due to 03.
The above findings indicate that we still have much to understand about 03-related effects. Responses to 03 may be measured in terms of decreases in FEV, or increases in symptoms, airway resistance, "nonspecific" airway reactivity, airway inflammation, lung permeability, or mucociliary clearance. However, many of these responses do not appear to be related when concurrently measured;6'7 this, in part, may be related to differences in response kinetics to 03. Even when portions of a neurophysiologic response mechanism are understood, the initiating events remain unknown. For example, inhaled 03 might stimulate airway C-fibers by a direct irritant effect, or indirectly by releasing mediators, or both. Multiple endogenous and exogenous factors influence the biologic response to 03, including genetics, dosimetry (the quantity of 03 available to react at a given location in the respiratory tract), nutrition, preexisting lung disease, and recent history of exposure, eg, to 03, other pollutants, or smoking. Rapid shallow breathing is a typical physiologic response to 03 exposure, which may protect against pathologic effects by altering dosimetry to reduce the overall dose to lung tissue. Thus, differences in ventilation patterns and resulting dosimetry might contribute to interindividual variability in 03 responses.8
What does all this mean to physicians, patients, and the general public? For researchers concerned with biomedical or public health issues, questions about 03 effects now appear more complex, and answers appear more tentative than before. Is there a common mechanism underlying the diverse manifestations of 03 response? Are inflammatory and other changes in the lungs physiologically adaptive or toxic? Are identifiable subgroups of the population consistently extrasusceptible to 03 effects? Which acute responses predict chronic 03 effects, if any? Lacking clear answers to these questions, clinicians
